KPTI vs. META

Last updated Apr 1, 2026

Compare and contrast key facts about Karyopharm Therapeutics Inc. (KPTI) and Meta Platforms, Inc. (META).

Performance

KPTI vs. META - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Karyopharm Therapeutics Inc. (KPTI) and Meta Platforms, Inc. (META). The values are adjusted to include any dividend payments, if applicable.

KPTI vs. META - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
KPTI Karyopharm Therapeutics Inc.	-24.32%	-27.45%	-21.82%	-74.56%	-47.12%	-58.46%	-19.25%	104.59%	-2.40%	2.13%
META Meta Platforms, Inc.	-13.25%	13.09%	66.05%	194.13%	-64.22%	23.13%	33.09%	56.57%	-25.71%	53.38%

Fundamentals

Market Cap KPTI : $100.14M META : $1.47T
EPS KPTI : -$16.68 META : $23.51
PS Ratio KPTI : 0.45 META : 7.32
Total Revenue (TTM) KPTI : $146.07M META : $200.97B
Gross Profit (TTM) KPTI : $140.12M META : $164.79B
EBITDA (TTM) KPTI : -$78.65M META : $104.55B

Returns By Period

In the year-to-date period, KPTI achieves a -24.32% return, which is significantly lower than META's -13.25% return. Over the past 10 years, KPTI has underperformed META with an annualized return of -27.27%, while META has yielded a comparatively higher 17.39% annualized return.

KPTI

• 1D: 5.09%
• 1M: -40.81%
• YTD: -24.32%
• 6M: -14.83%
• 1Y: 48.93%
• 3Y*: -54.30%
• 5Y*: -49.07%
• 10Y*: -27.27%

META

• 1D: 6.67%
• 1M: -11.66%
• YTD: -13.25%
• 6M: -21.96%
• 1Y: -0.42%
• 3Y*: 39.60%
• 5Y*: 14.06%
• 10Y*: 17.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

KPTI vs. META — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI

KPTI Risk / Return Rank: 60
KPTI Sharpe Ratio Rank: 60
KPTI Sortino Ratio Rank: 68
KPTI Omega Ratio Rank: 61
KPTI Calmar Ratio Rank: 58
KPTI Martin Ratio Rank: 55

META

META Risk / Return Rank: 40
META Sharpe Ratio Rank: 41
META Sortino Ratio Rank: 38
META Omega Ratio Rank: 37
META Calmar Ratio Rank: 42
META Martin Ratio Rank: 41

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KPTI vs. META - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and Meta Platforms, Inc. (META). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KPTI	META	Difference
Sharpe ratio Return per unit of total volatility	0.50	-0.01	+0.51
Sortino ratio Return per unit of downside risk	1.49	0.29	+1.20
Omega ratio Gain probability vs. loss probability	1.17	1.04	+0.13
Calmar ratio Return relative to maximum drawdown	0.69	-0.01	+0.71
Martin ratio Return relative to average drawdown	1.26	-0.04	+1.30
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KPTI vs. META - Sharpe Ratio Comparison

The current KPTI Sharpe Ratio is 0.50, which is higher than the META Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of KPTI and META, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	KPTI	META	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.50	-0.01	+0.51
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.52	0.32	-0.85
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.32	0.45	-0.77
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	0.55	-0.84

Correlation

The correlation between KPTI and META is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

KPTI vs. META - Dividend Comparison

KPTI has not paid dividends to shareholders, while META's dividend yield for the trailing twelve months is around 0.37%.

	TTM	2025	2024
KPTI Karyopharm Therapeutics Inc.	0.00%	0.00%	0.00%
META Meta Platforms, Inc.	0.37%	0.32%	0.34%

Drawdowns

KPTI vs. META - Drawdown Comparison

The maximum KPTI drawdown since its inception was -99.50%, which is greater than META's maximum drawdown of -76.74%. Use the drawdown chart below to compare losses from any high point for KPTI and META.

Drawdown Indicators

	KPTI	META	Difference
Max Drawdown Largest peak-to-trough decline	-99.50%	-76.74%	-22.76%
Max Drawdown (1Y) Largest decline over 1 year	-48.78%	-33.30%	-15.48%
Max Drawdown (5Y) Largest decline over 5 years	-98.36%	-76.74%	-21.62%
Max Drawdown (10Y) Largest decline over 10 years	-99.15%	-76.74%	-22.41%
Current Drawdown Current decline from peak	-99.21%	-27.41%	-71.80%
Average Drawdown Average peak-to-trough decline	-74.92%	-15.19%	-59.73%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.87%	13.13%	+13.74%

Volatility

KPTI vs. META - Volatility Comparison

Karyopharm Therapeutics Inc. (KPTI) has a higher volatility of 30.81% compared to Meta Platforms, Inc. (META) at 13.64%. This indicates that KPTI's price experiences larger fluctuations and is considered to be riskier than META based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KPTI	META	Difference
Volatility (1M) Calculated over the trailing 1-month period	30.81%	13.64%	+17.17%
Volatility (6M) Calculated over the trailing 6-month period	58.27%	26.73%	+31.54%
Volatility (1Y) Calculated over the trailing 1-year period	98.84%	39.91%	+58.93%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.10%	43.77%	+50.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	86.09%	38.46%	+47.63%

Financials